Indoco Remedies

Which are the latest news on Indoco Remedies?

Why is Indoco Remedies Ltd falling/rising?

As of 31-Jul, Indoco Remedies Ltd's stock price is rising to 219.55, reflecting a 1.18% increase after a trend reversal. However, the stock has significantly underperformed over the past year and five years, with ongoing financial struggles and decreased investor confidence.

As of 31-Jul, Indoco Remedies Ltd's stock price is rising, currently at 219.55, reflecting a change of 2.55 (1.18%) upward. This increase comes after a trend reversal where the stock gained after three consecutive days of decline. Additionally, the stock outperformed its sector by 0.25% today and reached an intraday high of Rs 224.2, which is a 3.32% increase.<BR><BR>Despite the positive movement today, the stock has shown significant underperformance over longer periods, with a -30.74% return over the past year and a -51.16% return over the last five years. The stock is trading at a discount compared to its peers' average historical valuations, which may attract some investors. However, the company has declared negative results for the last 15 consecutive quarters, indicating ongoing financial struggles.<BR><BR>Investor participation has decreased, with a delivery volume that fell by 45.31% against the five-day average, suggesting a lack of confidence among investors. Furthermore, the company has a high Debt to EBITDA ratio of 7.69 times, indicating low ability to service debt, which could be a concern for potential investors.<BR><BR>In summary, while the stock is experiencing a short-term rise, the long-term fundamentals remain weak, and the overall trend indicates significant challenges ahead for Indoco Remedies Ltd.

Should I buy, sell or hold Indoco Remedies Ltd?

Are Indoco Remedies Ltd latest results good or bad?

Indoco Remedies Ltd's latest results show a return to profitability with a net profit of ₹64.99 crores and a 6.33% revenue growth, but concerns about declining sequential revenue, high debt-to-equity ratio of 1.16x, and rising interest costs suggest caution for investors.

Indoco Remedies Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹64.99 crores for Q1 FY27, marking a significant turnaround from a loss of ₹35.79 crores in the same quarter last year. This is a positive indicator of profitability, especially as it reflects a dramatic improvement in operational performance.<BR><BR>Additionally, the company achieved a year-on-year revenue growth of 6.33%, reaching ₹467.50 crores, and improved its operating margin to 8.80% from 4.07% a year ago. These metrics suggest some operational recovery and better cost management.<BR><BR>However, there are significant concerns that temper this positive outlook. The sequential comparison shows a decline in revenue by 1.71% from the previous quarter, which raises questions about the sustainability of the profit increase. Furthermore, the company's debt-to-equity ratio has reached a concerning 1.16x, the highest in its recent history, indicating a precarious financial position. The rising interest costs, which grew by 47.83% over the last six months, further complicate the situation.<BR><BR>Overall, while the return to profitability and revenue growth are encouraging, the underlying issues related to debt and operational efficiency suggest that the results may not be as solid as they appear at first glance. Investors should be cautious and consider the broader financial context when evaluating Indoco Remedies Ltd's performance.

How big is Indoco Remedies?

As of 10th June, Indoco Remedies Ltd has a market capitalization of 1,906.00 Cr and reported net sales of 1,845.31 Cr, with a net loss of 95.15 Cr in the latest four quarters. Shareholder's funds are 1,022.00 Cr, and total assets are valued at 2,429.91 Cr.

As of 10th June, Indoco Remedies Ltd has a market capitalization of 1,906.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 1,845.31 Cr. However, it experienced a loss of 95.15 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's funds stood at 1,022.00 Cr, while total assets were valued at 2,429.91 Cr.

Who are in the management team of Indoco Remedies?

The management team of Indoco Remedies includes Suresh G Kare (Chairman & Wholetime Director), Aditi Kare Panandikar (Managing Director), Sundeep V Bambolkar (Joint Managing Director), and several independent non-executive directors. This diverse team provides strong leadership and oversight for the company.

The management team of Indoco Remedies includes the following key members:<BR><BR>1. **Suresh G Kare** - Chairman & Wholetime Director<BR>2. **Aditi Kare Panandikar** - Managing Director<BR>3. **Sundeep V Bambolkar** - Joint Managing Director<BR>4. **Rajiv Kakodkar** - Independent Non-Executive Director<BR>5. **D M Gavaskar** - Independent Non-Executive Director<BR>6. **Vasudha V Kamat** - Independent Non-Executive Director<BR>7. **Abhijit Y Gore** - Independent Non-Executive Director<BR>8. **Anand Nadkarni** - Non-Executive Director<BR><BR>This team brings a mix of leadership and independent oversight to the company.

Who are the peers of the Indoco Remedies?

Indoco Remedies' peers include Unichem Labs, Kwality Pharma, Venus Remedies, Hikal, NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Health, and Sakar Healthcare. Management risk is average for most peers, with varying growth and capital structure ratings, while Venus Remedies leads in 1-year returns at 268.68%, and Indoco Remedies has a return of -20.75%.

Peers: Indoco Remedies has the following peers: Unichem Labs., Kwality Pharma, Venus Remedies, Hikal, NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, while Average management risk is found at Unichem Labs., Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, Sakar Healthcare, and the rest. Growth is rated as Good for Unichem Labs. and Venus Remedies, while Below Average growth is noted for Kwality Pharma, Hikal, Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, and the rest. Capital Structure is rated as Excellent for Kwality Pharma, Venus Remedies, NGL Fine Chem, Windlas Biotech, and Amrutanjan Healt, while Below Average is noted for Hikal, Indoco Remedies, Hester Bios, and the rest, with Average capital structure at Sakar Healthcare.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 268.68%, while Hikal has the lowest at -52.29%. Indoco Remedies' 1-year return of -20.75% is better than Hikal's but worse than Venus Remedies'. Additionally, Hikal, Windlas Biotech, Amrutanjan Healt, and Sakar Healthcare all have negative six-month returns.

What does Indoco Remedies do?

Indoco Remedies Ltd is a Mumbai-based pharmaceutical company specializing in formulations, with a market capitalization of INR 1,906 Cr. As of March 2026, it reported net sales of 476 Cr and a net loss of 22 Cr.

Overview: <BR>Indoco Remedies Ltd is a Mumbai-based pharmaceutical company focused on formulations, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History: <BR>Indoco Remedies Limited was incorporated on August 23, 1947. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 476 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -22 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 1,906 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.10% <BR>Debt-Equity: 1.13 <BR>Return on Equity: -9.82% <BR>Price to Book: 2.02<BR><BR>Contact Details: <BR>Address: Indoco House 166 C S T Road, Santacruz (East) Kalina Mumbai Maharashtra : 400098 <BR>Tel: 91-022-26541851-55 <BR>Email: jagdishs@indoco.com <BR>Website: http://www.indoco.com

When is the next results date for Indoco Remedies Ltd?

The next results date for Indoco Remedies Ltd is 07 May 2026.

The next results date for Indoco Remedies Ltd is scheduled for 07 May 2026.

Is Indoco Remedies technically bullish or bearish?

As of December 2, 2025, Indoco Remedies exhibits a neutral technical trend with mixed signals, showing a mildly bearish outlook on weekly indicators and a lack of clear direction overall.

As of 2 December 2025, the technical trend for Indoco Remedies has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are bearish, while the monthly MACD and KST are mildly bullish, indicating a lack of clear direction. The Bollinger Bands are mildly bearish on both weekly and monthly charts, reinforcing the sideways trend. Daily moving averages show a mildly bullish stance, but this is countered by the overall bearish signals from the weekly indicators. The Dow Theory indicates a mildly bearish outlook on the weekly timeframe, while the monthly shows no trend. Overall, the strength of the current neutral stance is weak, driven primarily by conflicting signals across various indicators.

How has been the historical performance of Indoco Remedies?

Indoco Remedies has experienced fluctuating financial performance, with net sales decreasing to 1,664.92 Cr in March 2025 from 1,817.29 Cr in March 2024, and a significant drop in operating profit leading to a profit before tax of -74.37 Cr. Despite an increase in total assets, the company faces challenges in profitability, as reflected by a profit after tax of -77.95 Cr in March 2025.

Answer:<BR>The historical performance of Indoco Remedies shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Indoco Remedies reported net sales of 1,664.92 Cr in March 2025, a decrease from 1,817.29 Cr in March 2024, but an increase from 1,668.61 Cr in March 2023. The total operating income followed a similar pattern, with a total of 1,664.92 Cr in March 2025 compared to 1,817.29 Cr in the previous year. The total expenditure, excluding depreciation, was 1,565.66 Cr in March 2025, slightly down from 1,572.98 Cr in March 2024. Operating profit (PBDIT) decreased significantly to 99.26 Cr in March 2025 from 244.31 Cr in March 2024, leading to a profit before tax of -74.37 Cr in March 2025, a stark contrast to the profit of 135.80 Cr in March 2024. Consequently, profit after tax also fell to -77.95 Cr in March 2025 from 97.01 Cr in the previous year. The company's total assets increased to 2,429.91 Cr in March 2025 from 2,144.73 Cr in March 2024, while total liabilities rose to 2,429.91 Cr from 2,144.73 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 94.00 Cr in March 2025 from 155.00 Cr in March 2024, and the closing cash and cash equivalents were reported at 12.00 Cr in March 2025, down from 14.00 Cr in March 2024. Overall, the financial performance of Indoco Remedies reflects challenges in profitability despite growth in sales and total assets.

Is Indoco Remedies overvalued or undervalued?

As of May 23, 2025, Indoco Remedies is considered overvalued and risky due to troubling financial ratios, including a PE ratio of -33.83 and negative returns year-to-date, especially when compared to more profitable peers like Sun Pharma and Cipla.

As of 23 May 2025, the valuation grade for Indoco Remedies has moved from attractive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE ratio of -33.83, an EV to EBIT ratio of -240.53, and a ROE of -7.31%. These figures suggest that the company is struggling to generate profits and is not performing well compared to its peers.<BR><BR>In comparison to industry peers, Indoco Remedies stands out unfavorably; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights the challenges Indoco Remedies faces in the current market environment. Additionally, while the stock has recently outperformed the Sensex over the past week and month, its year-to-date and one-year returns remain negative, further reinforcing the notion that the stock is overvalued in light of its financial performance.

Who are the top shareholders of the Indoco Remedies?

The top shareholders of Indoco Remedies include Spa Holdings Pvt Ltd with 19.88%, mutual funds holding 18.52%, and individual investors owning 15.99%. Notably, Nippon Life India Trustee Ltd is the largest public shareholder with 4.8%.

The top shareholders of Indoco Remedies include a mix of promoters and institutional investors. The largest promoter is Spa Holdings Pvt Ltd, which holds 19.88% of the shares. The promoters collectively hold a significant portion of the company, with no pledged promoter holdings reported. <BR><BR>In terms of institutional investors, mutual funds hold 18.52% of the shares through 8 different schemes, while foreign institutional investors (FIIs) have a smaller stake of 1.24% across 39 entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund and holds 4.8%. Additionally, individual investors collectively own 15.99% of the company.

What is the bonus history of the Indoco Remedies?

Indoco Remedies issued a bonus share in a 1:2 ratio on May 17, 2012, with a record date of May 19, 2012. This is the most recent bonus action recorded for the company.

Indoco Remedies has a bonus history that includes a notable issue announced on May 17, 2012. The company issued a bonus in the ratio of 1:2, meaning that for every two shares held, shareholders received one additional share. The record date for this bonus was May 19, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Indoco Remedies or need further details, feel free to ask!

Has Indoco Remedies declared dividend?

Indoco Remedies Ltd has declared a 75% dividend, amounting to ₹1.5 per share, with an ex-date of September 19, 2024. Despite the dividend, the company's stock has experienced significant price declines over various periods, resulting in negative total returns in the short term.

Indoco Remedies Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.54%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.9%, with a dividend return of 0%, resulting in a total return of -14.9%.<BR><BR>Over the past year, the price return was -12.95%, the dividend return was 0.46%, leading to a total return of -12.49%.<BR><BR>In the 2-year period, the price return was -16.99%, the dividend return was 1.13%, culminating in a total return of -15.86%.<BR><BR>For the 3-year period, the price return was -27.73%, with a dividend return of 1.43%, resulting in a total return of -26.3%.<BR><BR>In the last 4 years, the price return was -29.74%, the dividend return was 1.73%, which led to a total return of -28.01%.<BR><BR>Over the 5-year period, the price return was 22.57%, with a dividend return of 3.36%, resulting in a total return of 25.93%.<BR><BR>Overall, while Indoco Remedies has declared a dividend, the total returns over various periods indicate significant price declines, particularly in the shorter terms, suggesting challenges in the company's stock performance despite the dividend declaration.